DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule chemotherapy that has recently completed a Phase 2 clinical trial for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer (NSCLC) and ovarian cancer.

We have also acquired certain commercial rights in China where VAL-083 is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients whose tumors exhibit features that make their cancer resistant to, or unlikely to, respond to currently available chemotherapy.

DelMar is dedicated to benefiting patients and creating shareholder value by rapidly developing and commercializing anti-cancer therapies in cancer indications where patients have failed, or are unlikely to respond to, modern therapy.

Breakthrough Cancer Therapeutics

STOCK HIGHLIGHTS

(as of 1/27/17)

$4.15	$43.2 M	36K	10.4 M
Share Price	Market Cap	Avg. Volume (3m)	Shares Outstanding

INVESTMENT HIGHLIGHTS

- **VAL-083**: A "First-in-class" small molecule chemotherapy
  - Unique anti-cancer mechanism overcomes chemo-resistance
  - NCI demonstrated clinical activity across a range of cancers
  - Promising interim outcomes data in refractory GBM clinical trial
    - Advancing to pivotal Phase III clinical trial
  - Pipeline expansion opportunities in high value oncology markets
  - Robust IP protection from newly issued patents
  - Orphan drug designation in USA and EU
- **Experienced Team with History of Success**
- **Solid Financial Position**
- **Transformational Near-term Catalysts**





VAL-083

VAL-083 is a "first-in-class," small-molecule chemotherapeutic, which means that the molecular structure of VAL-08 is not an analogue or derivative of other chemotherapies approved for the treatment of cancer.

In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated clinical activity against a range of cancers including lung, brain, cervical, and ovarian tumors as well as leukemia both as a single-agent and in combination with other treatments. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of malignant gliomas. DelMar recently announced that the USFDA's Office of Orphan Products has also granted orphan designations to VAL-083 for the treatment of medulloblastoma and ovarian cancer.

DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar® (temozolomide).

DelMar is advancing VAL-083 into a pivotal Phase III clinical trial in GBM patients whose tumors have progressed following standard treatment with temozolomide, radiotherapy, bevacizumab and a range of salvage therapies.

DelMar recently completed a Phase I/II clinical trial with VAL-083 in this patient population *(clinicaltrials.gov identifier: NCT01478178)*. Data from this study suggests that VAL-083 may offer a clinically meaningful survival benefit versus currently available salvage chemotherapy. Sub-group analysis suggested a dose-dependent survival benefit with improved survival at 6, 9 and 12 months following initiation of treatment with VAL-083 in a high versus low-dose sub group.

2017 Catalysis

- ✓ *Phase III trial in bevacizumab (Avastin™)-failed GBM*
- ✓ *Two Phase II trials in MGMT-unmethylated GBM*
  - ✓ *MD Anderson collaboration for first-recurrence of GBM*
  - ✓ *International Trial in newly diagnosed GBM*
- ✓ *Initiation of clinical trials in other solid tumor indications*
- ✓ *Collaboration and partnering opportunities*
- ✓ *Presentations at major scientific meetings*

MANAGEMENT TEAM

Jeffrey Bacha, BSc, MBA
Chairman & CEO

Dennis Brown, PhD
Chief Scientific Officer

Scott Praill, CPA
Chief Financial Officer

BOARD OF DIRECTORS

Jeffrey Bacha, BSc, MBA
Chairman & CEO

Dennis Brown, PhD
Chief Scientific Officer

John K. Bell, FCPA, FCA
Audit Committee Chair

Lynda Cranston, BScN, MScN, ICD.D
Governance & Compensation Committee Chair

Erich Mohr, PhD, R-Psych

Robert J. Toth, Jr., MBA

INVESTOR RELATIONS

T: (604) 629-5989
ir@delmarpharma.com

FOLLOW US:

DelMar PHARMACEUTICALS

Corporate Headquarters:
Suite 720 – 999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5

Clinical Operations:
3475 Edison Way, Suite R
Menlo Park, California 94025 USA